A Phase 1 Study of Brentuximab Vedotin Administered Sequentially and Concurrently With Multi-Agent Chemotherapy as Front-Line Therapy in Patients With CD30-Positive Mature T-Cell and NK-Cell Neoplasms, Including Systemic Anaplastic Large Cell Lymphoma

Trial Profile

A Phase 1 Study of Brentuximab Vedotin Administered Sequentially and Concurrently With Multi-Agent Chemotherapy as Front-Line Therapy in Patients With CD30-Positive Mature T-Cell and NK-Cell Neoplasms, Including Systemic Anaplastic Large Cell Lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Dec 2017

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications Anaplastic large cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T cell lymphoma; T-cell leukaemia
  • Focus Adverse reactions
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 10 Dec 2017 Results published in the Seattle Genetics (n=26) Media Release.
    • 10 Dec 2017 According to a Seattle Genetics media release, final five-year survival results (n=26) of the study were presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition.
    • 27 Jun 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top